Newsfeeds - Spark Newswire

1 minute read

Relmada Therapeutics Priced Upsized 8.82M Share Public Offering of Common Stock @$17/Share

Today, 8:32 PM

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the pricing of an upsized underwritten public offering of 8,823,530 shares of its common stock at a public offering price of $17.00 per share.

RLMD

10 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For November 18, 2021

By Benzinga Insights

Today, 8:32 PM

Upgrades

APP

10 minute read

Earnings Scheduled For November 11, 2021

By Benzinga Insights

Today, 8:32 PM

Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million.

ACHR

1 minute read

Relmada Therapeutics Sponsored Study Titled ‘A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) (RELIANCE-III)’ Posted On ClinicalTrials.gov; Study Is Recruiting

By Benzinga Newsdesk

Today, 8:32 PM

https://clinicaltrials.gov/ct2/show/NCT05081167

RLMD

2 minute read

Relmada Therapeutics Offers Regulatory, Development Updates For Ongoing Late-Stage Clinical Treatment For Major Depressive Disorder Candidate

By Benzinga Newsdesk

Today, 8:32 PM

Relmada is actively enrolling patients in RELIANCE III, a Monotherapy Registrational Phase 3 Study FDA Confirms Relmada Not Required to Conduct Two-Year Carcinogenicity Study and TQT Cardiac Study in Humans to Support

RLMD

1 minute read

Events
News

Relmada Therapeutics To Present At Oppenheimer Fall Healthcare Life Sciences, MedTech Summit Sept. 21 At 12:25 p.m. EDT

By Benzinga Newsdesk

Today, 8:32 PM

Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present

RLMD